Abstract:Background: Pravastatin is a potent cholesterol-lowering agent; similar to 34% of an oral dose of pravastatin is eliminated unchanged through biliary and urinary excretion. Rifampicin is an Inducer of drug metabolism enzymes, and it affects the activities of transporters involved in pravastatin disposition. Drug-drug interaction between rifampicin and pravastatin is possible because of the effects of rifampicin on the activities of drug transporters.Objective: This study was designed to Investigate the effects of a single oral dose of rifampicin on the pharmacokinetics of pravastatin.Methods: Healthy Chinese male volunteers were recruited for this 2-phase, single-blind, placebo-controlled, crossover study. The subjects were randomly divided into 2 groups to receive either rifampicin or placebo concomitantly with pravastatin. All subjects received a 20-mg oral dose of pravastatin on days 1 and 9, separated by an 8-day washout period. Subjects In the rifampicin group received a single 600-mg oral dose of rifampicin on day 1 and placebo on day 9; those in the placebo group received placebo on day 1 and a single 600-mg oral dose of rifampicin on day 9. High-performance liquid chromatography-tandem mass spectrometry was used to determine plasma concentrations of pravastatin for up to 12 hours after administration.Results: Twelve Volunteers participated in the study (6 per group). The mean (SD) age of the subjects was 20 (2) years (range, 18-25 years). The mean height of the subjects was 174 (4) cm (range, 168-180 cm), and the mean weight was 69.2 (3.7) kg (range, 65-77 kg). The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 130 [0.58] L . h(-1) . kg(-1) [P < 0.001]). No significant changes in the T(max) or t(1/2) of pravastatin were observed. All Subjects tolerated pravastatin well during both phases of the study, with Or Without coadministration of rifampicin. None of the Subjects withdrew from the study.Conclusion: Coadministration of a single oral dose of rifampicin significantly increased the plasma concentration of pravastatin in this group of healthy Chinese male subjects. (Clin Ther. 2009;31:1256-1263) (C) 2009 Excerpta Medica Inc.

Clinical pharmacokinetic study on Rifapentine

Inducing effect of rifampin (R) on CYP2C19 is related to gene dose

Pharmacokinetics of rifampin in healthy volunteers after a high oral dose

Study of 25-O-desacetylrifapentine Against Tubercle Bacillus Growth Activity

Pharmacokinetic studies and determination of plasma concentration of rifampicin in rats

Effects of a Concomitant Single Oral Dose of Rifampicin on the Pharmacokinetics of Pravastatin in a Two-Phase, Randomized, Single-Blind, Placebo-Controlled, Crossover Study in Healthy Chinese Male Subjects.

Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection

Rifapentine Vs. Rifampicin for the Treatment of Pulmonary Tuberculosis: a Systematic Review.

Growth, Characterization and Crystal Structure Analysis of Rifapentine

Pharmacokinetics of Rosuvastatin when Coadministered with Rifampicin in Healthy Males: A Randomized, Single-Blind, Placebo-Controlled, Crossover Study

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

Interaction of Rifabufin and Efavirenz on Pharmacokinetics in Rats

The Effect of Rifapentine and Rifampicin on Serum Voriconazole Levels Persist for 5 Days and 7 Days or More After Discontinuation in Tuberculosis Patients with Chronic Pulmonary Aspergillosis

Influence of Genetic Polymorphism of CYP2C19 on Rifampicin Individual Dosage Regimen in Pulmonary Tuberculosis Patients

Effect of a Single-Dose Rifampin on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

Crystal Modification of Rifapentine Using Different Solvents

Preparation, characterization, and pulmonary delivery of rifapentine liposomes modified by lauric diethanolamide

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

An Experimental Study of Rifampicin's Distribution in Different Tissues of Spinal Tuberculosis Patients

Quantification of rifampicin loaded into inhaled polymeric nanoparticles by reversed phase high-performance liquid chromatography in pulmonary nonphagocytic cellular uptake

Study on clinical pharmacokinetics of cefpiramide